-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8

Benzinga·11/24/2025 14:04:08
Listen to the news
Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $5 to $8.